title: [ADP receptor blockers: new insights in the therapy and prophylaxis of ischemic heart disease].
abstract: Adenosine diphosphate (ADP)-induced platelet activation plays a pivotal role in the thrombocyte aggregation and pathogenesis of ischemic heart disease. The long-term benefit of dual anti-platelet therapy with ADP-receptor antagonists, such as clopidogrel, in combination with aspirin is well established for patients following coronary stent implantation. This review discusses latest developments in the field of ADP-receptor antagonists.
authors.affiliation: Klinik III für Innere Medizin, Herzzentrum der Universität zu Köln, Germany. Natig.Gassanov@uk-koeln.de
authors.forename: N
authors.initials: N
authors.lastname: Gassanov
authors.forename: E
authors.initials: E
authors.lastname: Caglayan
authors.forename: E
authors.initials: E
authors.lastname: Erdmann
authors.forename: F
authors.initials: F
authors.lastname: Er
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy* / Q000517:prevention & control; D000249:Adenosine Monophosphate / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D015906:Angioplasty, Balloon, Coronary; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use; D000077144:Clopidogrel; D003131:Combined Modality Therapy; D006801:Humans; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000517:prevention & control; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D018048:Receptors, Purinergic P2 / Q000187:drug effects*; D015607:Stents; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D010975:Platelet Aggregation Inhibitors; D011725:Pyridines; D018048:Receptors, Purinergic P2; C446540:thienopyridine; D000249:Adenosine Monophosphate; C117446:cangrelor; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin